Mark For: LEADING THE NEXT GENERATION OF DRUG DELIVERY™ trademark registration is intended to cover the categories of human pharmaceuticals to treat central nervous system diseases and disorders, cancer, ADHD, and pain; transdermal pain patches, and liposomes to encapsulate and deliver medications. [all]
Status
2022-04-26 UTC
DEAD APPLICATION Refused Dismissed or Invalidated
This trademark application was refused, dismissed, or invalidated by the Office and this application is no longer active.
TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED 2007-12-10
Basis
1(a)
Class Status
ACTIVE
Primary US Classes
006:
Chemicals and Chemical Compositions
018:
Medicines and Pharmaceutical Preparations
044:
Dental, Medical and Surgical Appliances
046:
Foods and Ingredients of Foods
051:
Cosmetics and Toilet Preparations
052:
Detergents and Soaps
Primary International Class
005 - Primary Class
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
Yes
Current Use
Yes
Intent To Use
No
Filed ITU
No
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Laurence S. Rickles
Law Office Assigned
L70
Employee Name
ENGEL, MICHAEL L
Timeline
2005-01-00
Date of First Use
2005-01-01
Date of First Use
2005-01-01
Date of Use In Commerce
2006-06-07
Application Filed
2007-11-15
Abandon
2007-12-10
Location: TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED
2007-12-10
Status: Abandoned because the applicant failed to respond or filed a late response to an Office action. To view all documents in this fi
LAURENCE S. RICKLES JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NEW JERSEY 08933-7001
Good, Services, and Codes
(ABANDONED) IC 005. US 006 018 044 046 051 052. G & S: human pharmaceuticals to treat central nervous system diseases and disorders, cancer, ADHD, and pain; transdermal pain patches, and liposomes to encapsulate and deliver medications. FIRST USE: 20050100. FIRST USE IN COMMERCE: 20050100
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
Type Code
Type
GS0051
human pharmaceuticals to treat central nervous system diseases and disorders, cancer, ADHD, and pain; transdermal pain patches, and liposomes to encapsulate and deliver medications
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.